Share this entry
Crizotinib offered a 71.7% objective response rate (ORR) and a median duration of response (DOR) of 19.7 months in East-Asian non-small cell lung cancer (NSCLC) patients harbouring c-ros oncogene 1 (ROS1) rearrangements. This was concluded by investigators from China, Japan, South-Korea, and Taiwan who published the results of the trial in the Journal of Clinical Oncology (JCO) on March 29, 2018.
The Phase II open-label study enrolled 127 East-Asian patients with confirmed ROS1-positive NSCLC who had received up to three prior lines of systemic therapy. Participants received two oral doses of 250 mg crizotinib daily until progression disease (RECIST 1.1) as confirmed by an independent radiological review (IRR). The primary efficacy endpoint was ORR by IRR.
At the time of the data cut-off, 49.6% of patients were still receiving crizotinib-treatment. Seventeen complete responses and 74 partial responses (Figure 1) were observed, translating into an ORR of 71.7% (95% CI, 63.0% – 79.3%) by IRR. Responses were lasting, the median DOR was 19.7 months (95% CI, 14.1 months – not reached), and irrespective of the number of prior lines of therapy The median progression-free survival (PFS) by IRR was 15.9 months (95% CI, 12.9 – 24.0).
The authors reported no new toxicities. The most common adverse reactions which occur in ≥25% of patients treated with crizotinib are vision disorders, nausea, diarrhoea, vomiting, oedema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory tract infection, dizziness, and neuropathy.
- Wu YL et al. J Clin Oncol 2018;JCO2017755587 DOI: 10.1200/JCO.2017.75.5587
- Pfizer Inc. XalkoriⓇ (crizotinib) USPI, revised 2/2018
Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.
YOU MAY ALSO LIKE
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd. – Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations – XalkoriⓇ/crizotinib in Asian non-small cell lung cancer patients with ROS-1 alterations